Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company whose news flow centers on the development of immunotherapy medicines based on halogenated xanthenes, particularly its lead molecule rose bengal sodium. As an OTCQB-traded company, Provectus regularly issues updates on preclinical and clinical research, investor events, and corporate initiatives that shape the outlook for its investigational programs.
News about Provectus often highlights progress with PV-10, the company’s rose bengal sodium-based investigational cancer immunotherapy. Recent announcements have covered preclinical studies in head and neck squamous cell carcinoma, orthotopic bladder cancer models using oral and intravesical PV-10, and mechanistic work showing activation of the STING immune pathway and enhanced T-cell responses in vaccine settings. These items provide insight into how the company is exploring PV-10 across oncology and immunology applications.
Investors and researchers following PVCT can also expect updates on wound healing and dermatology research, such as non-clinical data on full-thickness cutaneous wounds, as well as ophthalmology developments through the VisiRose founded entity focused on rose bengal sodium-based eye therapies. Additional news items include announcements of annual stockholder meetings, investor webinars, and conference calls, which offer company updates and access to management presentations.
This PVCT news page aggregates these disclosures in one place, making it easier to review Provectus’s latest scientific publications, collaboration highlights, and corporate communications. For anyone tracking the evolution of its rose bengal sodium platform across oncology, dermatology, ophthalmology, infectious diseases, and tissue repair research, this feed provides an organized view of the company’s reported milestones and ongoing activities.
Provectus announced that the USPTO has allowed patent application 16/412,872, which pertains to the use of PV-10, an injectable formulation of rose bengal disodium, for treating relapsed and refractory pediatric solid tumor cancers. This patent represents the initial intellectual property from the company's collaboration with Dr. Aru Narendran at the University of Calgary. The patent supports both monotherapy and combined treatments with immune checkpoint blockade or radiotherapy. Provectus aims to further develop its intralesional oncology drug program to enhance cancer treatment options.
Provectus (OTCQB: PVCT) announced that H. Lee Moffitt Cancer Center will present non-clinical data on PV-10, an injectable cancer immunotherapy using rose bengal disodium (RBD), at the SITC 2020 Annual Meeting (Nov 9-14, 2020). The presentation will include research on the drug's efficacy, especially in combination with chemotherapy for pancreatic cancer. PV-10 aims to induce immunogenic cell death in tumors through lysosome disruption. This follows previous positive findings on RBD's immune responses in various cancers, with ongoing clinical studies for adult and pediatric solid tumor cancers.
Provectus (OTCQB: PVCT) has completed enrollment of 12 patients in its Phase 1 study of PV-10, an injectable cancer immunotherapy targeting neuroendocrine tumors (NET) that are resistant to standard treatments. The therapy utilizes rose bengal disodium (RBD) to induce cell death in tumors. The primary focus is on safety, with secondary endpoints assessing response rates and receptor expressions. The company plans to engage with Australia’s Therapeutic Goods Administration for an end-of-phase meeting in Q1 2021.